Article Text

Download PDFPDF
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
  1. Luisa Costa,
  2. Marco Tasso,
  3. Nadia Scotti,
  4. Erika Mostacciuolo,
  5. Nicolò Girolimetto,
  6. Francesca Foglia,
  7. Antonio del Puente,
  8. Raffaele Scarpa,
  9. Francesco Caso
  1. Rheumatology Unit, Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II Scuola di Medicina e Chirurgia, Napoli, Campania, Italy
  1. Correspondence to Professor Raffaele Scarpa, University of Naples Federico II School of Medicine and Surgery, 80138 Napoli, Italy; rscarpa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Gupta et al 1 who reported the management of treatments for rheumatic diseases during COVID-19 pandemic among practitioners in India. In this study, the authors showed that about half of the physicians would reduce the use of biological disease-modifying antirheumatic drugs (bDMARDs) or defer specific drugs such as rituximab.1 Choices were apparently made considering possible relationships between drug mechanism of action and effect on the viral infection.1

During COVID-19 pandemic, telemedicine is emerging as a possible tool for reducing the risk of contagion and viral spread,2–4 and a useful strategy for the management of chronic diseases.5 6

As of 29 April 2020, the outbreak of COVID-19 generated 201 505 confirmed cases in Italy, with 2405 confirmed cases in Naples Metropolitan area.

The objective of our study was to evaluate telemedicine when offered as part of routine care for the follow-up of patients …

View Full Text


  • Contributors All authors participated in the interpretation and analysis of data, and in drafting and critical revision of the work. All authors approved the final version of the manuscript. LC, NG, AdP, RS and FC: contributed to study conception and/or design of the work. MT, NS, EM and FF: contributed to the acquisition of data.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles